Update on the therapy for myelodysplastic syndrome.

Update on the therapy for myelodysplastic syndrome.

Item
http://www.wikidata.org/entity/Q37385953
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trialPesticide exposure as a risk factor for myelodysplastic syndromes: a meta-analysis based on 1,942 cases and 5,359 controlsPredicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score systemSignificant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndromeNeighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States.An unexpected complication after periorbital tumor surgery in a patient later discovered to have myelodysplasia.Palliative and End-of-Life Care in Myelodysplastic Syndromes.Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
P2860

Update on the therapy for myelodysplastic syndrome.

Item
http://www.wikidata.org/entity/Q37385953
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Update on the therapy for myelodysplastic syndrome.
@en
Update on the therapy for myelodysplastic syndrome.
@nl
type
label
Update on the therapy for myelodysplastic syndrome.
@en
Update on the therapy for myelodysplastic syndrome.
@nl
prefLabel
Update on the therapy for myelodysplastic syndrome.
@en
Update on the therapy for myelodysplastic syndrome.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Update on the therapy for myelodysplastic syndrome.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698